TIAN YUAN GP (06119) establishes subsidiary to enter the healthcare industry, planning to launch new business related to China's large health industry.

TIAN YUAN GP (06119) announced that the group plans to develop new business related to the Chinese healthcare industry. In order to promote the development and implementation of the new business, the company has established a wholly-owned subsidiary in Hong Kong and appointed Mr. Wu Yu as the general manager of the newly established subsidiary company. Mr. Wu will be responsible for strategic planning, business development, and operational matters of the group's new business. Mr. Wu has rich professional knowledge and experience in the medical and management fields. He obtained a Bachelor's degree in Medicine from Wuhan University in 2003 and a Master's degree in Business Administration from Guangdong University of Finance and Economics in 2019. Mr. Wu is currently a licensed practicing physician in China and holds positions such as Deputy General Manager of Guangdong Yuexiang Tianyuan Health Industry Co., Ltd. and Director of Zhanjiang Tianyuan Nanyou Comprehensive Hospital Co., Ltd. With his comprehensive background in healthcare management and hospital operations, Mr. Wu has the advantage of leading the group into the healthcare industry. The group is mainly engaged in bulk cargo handling services, related value-added port services, and the supply and sale of oil products. In addition to developing its core business, the company has also been exploring the possibility and opportunities of new businesses to achieve diversified development, expand its business portfolio, broaden revenue sources, and strengthen future profitability and development potential. The group has identified the business opportunities brought by the large healthcare industry, especially with the trend of aging population in China and the increasing demand for health management. The Chinese healthcare industry has significant growth potential and is supported by strong national strategies such as "Healthy China 2030" and the 14th and 15th Five-Year Plans. The Chinese government has elevated the development of the healthcare industry to a national strategic priority area and provides long-term stable policy support for areas including innovative drugs, advanced medical equipment, and digital healthcare. These policies not only promote technological innovation, such as integrating artificial intelligence with healthcare and promoting digital health solutions, but also address population aging and other demographic changes. This creates a substantial amount of market opportunities, covering areas such as smart aging care, health management, preventive medicine, and environmental health technology. Additionally, continuous reforms in the healthcare system, medical insurance, and pharmaceutical sectors are enhancing the industry ecosystem and driving high-quality development. In this context, the company sees great prospects in investing in the Chinese healthcare industry, aiming to create long-term value with the support of policies, technological advancements, and growing market demand, and contribute to the improvement of health and well-being in China.